Selank is a synthetic seven-amino-acid peptide derived from tuftsin, a small immune-modulating fragment that occurs naturally in the body. Russian researchers developed it in the 1990s as an anxiolytic alternative that might offer the calming effects of benzodiazepines without the sedation, dependence, or cognitive dulling those drugs typically bring.
Three decades of laboratory and clinical work have positioned Selank as one of the most studied peptides in the anxiety and stress-resilience space. It's been examined for effects on anxiety, memory, withdrawal symptoms, immune signaling, and brain connectivity, and a consistent picture has emerged: Selank appears to modulate the GABA system — the brain's primary calming network — while also touching neurotrophin and cytokine pathways involved in mood and resilience.
What makes Selank distinctive is that it seems to produce benzodiazepine-like calming through gentler mechanisms. Rather than directly activating GABA receptors, it appears to shift gene expression and signaling in ways that support the body's own regulatory systems, which may explain why studies have not reported the sedation or dependence patterns associated with classical anxiolytics.
Selank and Anxiety Reduction
The anxiolytic properties of Selank are its most thoroughly investigated feature. In studies using the elevated plus maze — a standard test for anxiety-related behavior — Selank produced calming effects comparable to diazepam, a classical benzodiazepine (5). When administered alongside diazepam under chronic stress conditions, the combination normalized anxiety markers back to pre-stress baseline, suggesting Selank may potentiate or complement benzodiazepine action through overlapping pathways (5).
Molecular work has begun to clarify how this happens. Analysis of 84 neurotransmission-related genes in the frontal cortex showed that Selank altered expression of 45 genes within an hour of administration, with changes that strongly correlated with those produced by GABA itself (7). This suggests Selank acts as an allosteric modulator of the GABAergic system — meaning it doesn't bind the receptor's main site like a benzodiazepine, but instead shifts the system's tone from a different angle. Cell-culture studies reinforced this: Selank alone produced no direct change in GABA gene expression, but when paired with GABA it nearly suppressed GABA's own gene-expression effects, consistent with a fine-tuning rather than activating role (6).
A human neuroimaging study using resting-state fMRI in 52 participants found that intranasal Selank altered functional connectivity between the right amygdala — a key anxiety hub — and regions of the right temporal cortex (2). This represents one of the first direct visualizations of Selank's acute effects on the human brain.
Selank and Stress Resilience
Beyond acute anxiety, Selank has been studied for how it helps the body weather chronic stress. In a chronic foot-shock stress paradigm, untreated subjects developed liver damage — hepatocyte degeneration, focal necrosis, and immune cell infiltration — reflecting the systemic toll of prolonged stress (3). Selank administration reduced these degenerative changes across all doses tested, with a 300 µg/kg dose producing the strongest protective effect and restoring normal cellular architecture in liver tissue (3).
The protective effect appears to extend to the immune-signaling layer of the stress response. In a social-confrontation stress model, stressed subjects showed elevated levels of inflammatory cytokines — IL-1β, IL-6, TNF-α, and TGF-β1 — molecules that drive the chronic inflammation linked to stress-related illness (8). Selank treatment reduced these inflammatory markers back toward control values while also restoring IL-4, an anti-inflammatory signal. This cytokine-balancing effect may be part of why Selank's reputation extends beyond pure anxiolysis into general stress resilience.
Selank and Memory and Cognition
Selank's cognitive effects have been studied in the context of chronic alcohol exposure, a model of long-term neurological wear-and-tear. Subjects exposed to ethanol for 30 weeks developed memory and attention deficits during withdrawal, measured by performance on object recognition tasks (4). A seven-day course of Selank prevented these cognitive disturbances and also produced a measurable cognitive-stimulating effect in subjects who had not been exposed to ethanol at all.
The mechanism appears to involve BDNF — brain-derived neurotrophic factor, a key signaling protein that supports the formation and maintenance of neural connections. Chronic ethanol exposure had elevated BDNF in the hippocampus and frontal cortex in a dysregulated way, and Selank normalized these levels (4). This neurotrophin-modulating effect may explain why Selank seems to support cognition without acting as a stimulant — it appears to restore signaling balance rather than push the system harder.
Selank and Withdrawal and Dependence
One of the more striking findings in the Selank literature concerns its effect on withdrawal from opiates. In a model of naloxone-precipitated morphine withdrawal, a single injection of Selank reduced the total withdrawal syndrome index by nearly 40%, significantly attenuating convulsions, posture disturbances, and the drooping eyelid pattern characteristic of withdrawal (1). It also raised tactile sensitivity thresholds nine-fold compared to active control, suggesting it dampened the hyperalgesic state that makes withdrawal so distressing.
Selank's effects in this context were close to — though slightly less pronounced than — those of diazepam, but with an important difference: Selank itself does not appear to produce dependence in the way benzodiazepines do. This combination of withdrawal-attenuating activity without its own dependence liability is a key reason researchers have continued investigating peptide-based anxiolytics as alternatives to classical sedatives.